• 1. Asymmetric synthesis of (3S?)-2,3,4,5-tetrahydropyridazine-3-carboxylic acid and its methyl ester??
  Ian H. Aspinall,Phillip M. Cowley,Glynn Mitchell,Clive M. Raynor,Richard J. Stoodley J. Chem. Soc. Perkin Trans. 1 1999 2591
• 2. Transmission of substituent effects in pyridines. Part IV. Alkaline hydrolysis of methyl diazinecarboxylates
  L. W. Deady,D. J. Foskey,R. A. Shanks J. Chem. Soc. B 1971 1962
• 3. Investigation of electronic effects in diazine rings. Linear free energy relationships in the reactivity of diazine mono- and di-carboxylates
  Milica Mi?i?-Vukovi?,Mirjana Radojkovi?-Veli?kovi?,Vojislav Jezdi? J. Chem. Soc. Perkin Trans. 2 1990 109

Recent Advances in the Application of Methyl pyridazine-3-carboxylate (CAS: 34253-02-6) in Chemical Biology and Pharmaceutical Research

Methyl pyridazine-3-carboxylate (CAS: 34253-02-6) has emerged as a versatile scaffold in chemical biology and pharmaceutical research, with recent studies highlighting its potential in drug discovery and development. This compound, characterized by its pyridazine core and ester functionality, has been investigated for its role in modulating biological targets, including enzymes and receptors. The growing interest in this molecule is reflected in the increasing number of publications and patents exploring its synthetic utility and pharmacological properties.

Recent research has focused on the synthesis and derivatization of Methyl pyridazine-3-carboxylate to enhance its bioactivity and selectivity. A study published in the Journal of Medicinal Chemistry (2023) demonstrated the compound's efficacy as a precursor for the development of kinase inhibitors. The researchers utilized a structure-activity relationship (SAR) approach to optimize the ester moiety, resulting in derivatives with improved binding affinity and pharmacokinetic profiles. These findings underscore the potential of Methyl pyridazine-3-carboxylate as a key intermediate in the design of targeted therapies.

In addition to its role in kinase inhibition, Methyl pyridazine-3-carboxylate has been explored for its applications in antimicrobial and anti-inflammatory agents. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported the synthesis of novel pyridazine-based analogs exhibiting potent activity against multidrug-resistant bacterial strains. The researchers attributed the observed bioactivity to the compound's ability to disrupt bacterial cell wall synthesis, highlighting its promise as a lead structure for antibiotic development.

The mechanistic insights into Methyl pyridazine-3-carboxylate's biological activity have also been a focus of recent investigations. Advanced computational modeling and X-ray crystallography studies have elucidated its binding modes with various protein targets. For instance, a collaborative study between academic and industrial researchers (Nature Communications, 2023) revealed the compound's unique interactions with the active site of a cancer-related protease, providing a structural basis for further optimization.

Despite these advancements, challenges remain in the clinical translation of Methyl pyridazine-3-carboxylate-based therapeutics. Issues such as metabolic stability and off-target effects are areas of active research. Recent efforts have employed prodrug strategies and formulation technologies to address these limitations, as documented in a 2024 review in Advanced Drug Delivery Reviews. These developments highlight the ongoing innovation in harnessing the potential of this compound for therapeutic applications.

In conclusion, Methyl pyridazine-3-carboxylate (CAS: 34253-02-6) continues to be a valuable scaffold in chemical biology and pharmaceutical research. Its diverse applications, from kinase inhibitors to antimicrobial agents, demonstrate its versatility and potential for addressing unmet medical needs. Future research directions may include the exploration of its use in combination therapies and the development of more sustainable synthetic routes. As the field progresses, this compound is poised to play an increasingly important role in drug discovery pipelines.

• 65202-57-5(6-fluoro-3-Pyridazinecarboxylic acid methyl ester)
• 106584-51-4(Methyl 6-methylpyridazine-3-carboxylate)
• 64210-57-7(Ethyl 6-methylpyridazine-3-carboxylate)
• 15366-34-4(methyl 1H-pyrazole-5-carboxylate)
• 1126-10-9(Ethyl pyridazine-3-carboxylate)
• 217447-50-2(3-Pyridazinecarboxylicacid, 2,3,4,5-tetrahydro-4-hydroxy-, methyl ester, (3R,4R)-)
• 1044741-82-3(3-Cinnolinecarboxylic acid methyl ester)
• 2164-61-6(Pyridazine-3-carboxylic acid)
• 57266-70-3(H2DCP)
• 64210-60-2(6-Methylpyridazine-3-carboxylic acid)